However, paianpulima (a novel PD-1 inhibitor) was reintroduced after improvement of the myocarditis and a significant decrease in the level of fasting C-peptide was observed (598.8 pmol/L to 221.1 pmol/L). The gene discussed is PDCD1; the disease is myocarditis.